First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF ®10b
Conditions: Healthy Interventions: Biological: H107e; Biological: CAF ®10b; Biological: H107e/CAF®10b - low adjuvant dose; Biological: H107e/CAF®10b - full adjuvant dose; Biological: Low dose intranasal H107e; Biological: Full dose intranasal H107e; Biological: H107e/CAF®10b; Biological: i.m. placebo; Biological: BCG; Biological: i.d. placebo; Biological: Intranas al H107e Sponsors: Statens Serum Institut; Aurum Institute; Bill and Melinda Gates Foundation; Leiden University Medical Center; South African Tuberculosis Vaccine Initiative Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials
Endurance Training in Patients With Post-TB Lung Disease
Conditions: Tuberculosis; Post-Tuberculous Pleural Fibrosis; Post-Tuberculous Bronchiectasis Interventions: Other: Experimental; Other: Control Sponsor: Riphah International University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
Condition: Rifampicin Susceptible Pulmonary Tuberculosis Interventions: Drug: RESP301; Drug: HRZE Sponsor: Thirty Respiratory Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
